



CLAIMS


1. A compound, an isotopically labeled compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:




.


2. The compound according to claim 1, the isotopically labeled compound, or the pharmaceutically acceptable salt thereof, wherein the compound is


.

3. The compound according to claim 1, the isotopically labeled compound, or the pharmaceutically acceptable salt thereof, wherein the compound is


.

4. The compound according to claim 1, the isotopically labeled compound, or the pharmaceutically acceptable salt thereof, wherein the compound is



.

5. A pharmaceutical composition comprising a therapeutically effective amount of the compound, the isotopically labeled compound, or the pharmaceutically acceptable salt thereof, according to any one of claims 1-4.

6. The pharmaceutical composition according to claim 5, further comprising one or more pharmaceutically acceptable auxiliary materials.

7. The pharmaceutical composition according to claim 5, further comprising one or more additional therapeutic agents.

8. Use of the compound according to any one of claims 1-4, the isotopically labeled compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to any one of claims 5-7 for the manufacturing of a medicament for preventing or treating a disease or disorder mediated by activation of the complement alternative pathway.

9. The use according to claim 8, wherein the disease or disorder mediated by activation of the complement alternative pathway is selected from paroxysmal nocturnal hemoglobinuria (PNH), primary glomerulonephritis (IgAN), membranous nephropathy (MN), C3 glomerulonephritis (C3G), age-related macular degeneration (AMD), geographic atrophy (GA), atypical hemolytic uremic syndrome (aHUS), hemolytic uremic syndrome (HUS), diabetic retinopathy (DR), and myasthenia gravis (MG).